|

Placebo matching for Selinexor (combination therapy) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2/3: 1

Top Sponsors

  • Karyopharm Therapeutics Inc1

Indications

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma1
  • Cancer1

Chandler, Arizona1 trial

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.